Navigation Links
Ben-Gurion U. and Sorrento Therapeutics sign agreement to develop anti-hepatitis C virus antibodies
Date:7/9/2013

SAN DIEGO AND BEER-SHEVA, ISRAELJuly 9, 2013 -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and B.G. Negev Technologies and Applications Ltd., the technology transfer company of Ben-Gurion University of the Negev (BGU), have announced an option and license agreement to develop therapeutic products to treat Hepatitis C Virus (HCV).

"We are pleased to be collaborating with Sorrento to develop our fully human anti-HCV antibody clones into potential anti-HCV therapeutics," said Leslie Lobel, M.D., Ph.D., a lecturer and vice chair of the Department of Microbiology, Immunology and Genetics in BGU's Faculty of Health Sciences. Dr. Lobel identified the antibody clones from patients who have recovered from HCV infections.

According to the Centers for Disease Control (CDC), more than 170 million people worldwide are chronically infected with Hepatitis C Virus (HCV), including approximately 3.2 million people in the United States.

This collaborative effort utilizes the respective strengths of each organization to create an important product opportunity consisting of therapeutic and/or prophylactic agents against HCV infections. Sorrento, a San Diego-based company, will be responsible for developing the anti-HCV antibody products.

"Sorrento has already achieved many successes using its proprietary G-MAB library to identify, characterize and develop fully human antibodies against difficult targets relevant to infectious agents," said Henry Ji, Ph.D., president and chief executive officer of Sorrento.

"We are excited to be working with Dr. Lobel to add a program targeting HCV to our existing portfolio of therapeutic antibodies for the prevention and/or treatment of major infectious diseases." Doron Krakow, executive vice president of American Associates, Ben-Gurion University of the Negev said, "It is exciting that another medical breakthrough emanating from BGU's research laboratories will potentially become a product that could help people suffering from hepatitis.

"Dr. Lobel was a pioneer at BGU, born and educated in the U.S., who chose to establish his research in the Negev Desert rather than at a top American medical university, so this is a truly significant development," Krakow added.


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related medicine news :

1. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
2. Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture
3. Viewing terrorist attacks on TV increases pain intensity -- Ben-Gurion U. researchers
4. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
5. Lauren Sciences LLCs research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIV
6. Non-invasive treatment for children with obstructive sleep apnea suggested by Ben-Gurion University study
7. Ben-Gurion U and Cincinnati Childrens Hospital to develop new pediatric medical devices
8. Israel rocket attacks increase miscarriage likelihood -- Ben-Gurion U. research study
9. Targeted therapeutics for colon cancer to be presented at AACR meeting
10. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
11. FORMA Therapeutics teams with TGen Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: